Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Split virion, inactivated Influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Age 16 to 60 years |
| Group 2 | EXPERIMENTAL | Age over 60 years |
| Name | Type | Description |
|---|---|---|
| Split virion, inactivated Influenza vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM) |
Inclusion Criteria : * Aged 18 to 60 years or 61 years and older on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method ...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
The split virion, inactivated influenza vaccine is an injectable vaccine developed by Sanofi for the prevention of influenza. It is a split-virion formulation, meaning the virus is inactivated and broken apart so the vaccine can prompt an immune response without causing infection. It is being studied in adults.
It is used for the prevention of influenza, a respiratory infection caused by influenza viruses. The vaccine is designed to protect against seasonal influenza strains. Sanofi's Northern Hemisphere 2008-2009 formulation was tested in healthy adult volunteers aged 18 years and older in the United Kingdom.
Sanofi develops the split virion, inactivated influenza vaccine. Sanofi is a global pharmaceutical company that trades under the ticker SNY. The company's vaccine business is one of the largest in the world, and influenza vaccines are a core part of that portfolio.
The split virion, inactivated influenza vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA for the formulation described here. The Phase 2 study evaluating this formulation has been completed.
The split virion, inactivated influenza vaccine was evaluated in one completed Phase 2 trial, NCT00718146, titled Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation. The trial enrolled 130 healthy adult volunteers aged 18 years and older in the United Kingdom and used a controlled design.